Cardiovascular risk associated with the metabolic syndrome

Current Diabetes Reports

Volumn 4, Issue 1, 2004, Pages 63-68

  Lindsay, Robert S ^a   Howard, Barbara V ^a  

^a MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; TRIACYLGLYCEROL;

ARTERIAL PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; GENETIC DISORDER; GLUCOSE BLOOD LEVEL; HEREDITY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PREVALENCE; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; ADIPOCYTE; METABOLISM; PATHOPHYSIOLOGY; RISK FACTOR;

ADIPOCYTES; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; RISK FACTORS;

EID: 1642360692     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-004-0013-9     Document Type: Review

References (49)

1. Liese AD, Mayer-Davis EJ, Haffner SM: Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol Rev 1998, 20: 157-172.
2. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37: 1595-1607.
3. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1999, 15: 539-553.
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [no authors listed]. Circulation 2003, 106: 3143-3420.
5. Haffner SM, Valdez RA, Hazuda HP, et al.: Prospective analysis of the insulin-resistance syndrome (syndrome X . Diabetes 1992, 41: 715-722.
6. Barker DJ: Fetal and infant origins of adult disease. BMJ 1990, 301: 1111.
7. Dietz WH: Critical periods in childhood for the development of obesity. Am J Clin Nutr 1994, 59: 955-959.
8. Meigs JB: Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000, 152: 908-911.
9. Kuusisto J, Lempiainen P, Mykkanen L, Laakso M: Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. Diabetes Care 2001, 24: 1629-1633.
10. Hanson RL, Imperatore G, Bennett PH, Knowler WC: Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 2002, 51: 3120-3127.
11. Freeman DJ, Norrie J, Sattar N, et al.: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103: 357-362.
12. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359: 995-1003.
13. Barroso I, Gurnell M, Crowley VE, et al.: Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999, 402: 880-883.
14. Savage DB, Tan GD, Acerini CL, et al.: Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 2003, 52: 910-917.
15. Altshuler D, Hirschhorn JN, Klannemark M, et al.: The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000, 26: 76-80.
16. Ridker PM, Cook NR, Cheng S, et al.: Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 2003, 23: 859-863.
17. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340: 115-126.
18. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342: 836-843.
19. Pickup JC, Crook MA: Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998, 41: 1241-1248.
20. Schmidt MI, Duncan BB, Sharrett AR, et al.: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999, 353: 1649-1652.
21. Festa A, D'Agostino RB, Tracy RP, Haffner SM: Elevated levels of acute phase proteins and plasminogen activator inhibitor-1 (PAI-1) predict the development of type 2 diabetes mellitus: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes 2002, 51: 1131-1137.
22. Hundal RS, Petersen KF, Mayerson AB, et al.: Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002, 109: 1321-1326.
23. Hotamisligil GS: The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999, 245: 621-625.
24. Hu E, Liang F, Spiegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996, 271: 10697-10703.
25. Hotta K, Funahashi T, Arita Y, et al.: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20: 1595-1599.
26. Weyer C, Funahashi T, Tanaka S, et al.: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86: 1930-1935.
27. Yang WS, Lee WJ, Funahashi T, et al.: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001, 86: 3815-3819.
28. Maeda N, Takahashi M, Funahashi T, et al.: PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50: 2094-2099.
29. Lindsay RS, Funahashi T, Matsuzawa Y, et al.: Adiponectin protects against development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360: 57-58.
30. Ouchi N, Kihara S, Arita Y, et al.: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102: 1296-1301.
31. Ouchi N, Kihara S, Arita Y, et al.: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 199, 100: 2473-2476.
32. Matsuda M, Shimomura I, Sata M, et al.: Role of adiponectin in preventing vascular stenosis- the missing link of adipovascular axis. J Biol Chem 2002, 277: 37487-37491.
33. Zoccali C, Mallamaci F, Tripepi G, et al.: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002, 13: 134-141.
34. Steppan CM, Bailey ST, Bhat S, et al.: The hormone resistin links obesity to diabetes. Nature 2001, 409: 307-312.
35. Way JM, Gorgun CZ, Tong Q, et al.: Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2001, 276: 25651-25653.
36. Verma S, Li SH, Wang CH, et al.: Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003, 108: 736-740.
37. Savage DB, Sewter CP, Klenk ES, et al.: Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001, 50: 2199-2202.
38. Katz JR, Mohamed-Ali V, Wood PJ, et al.: An in vivo study of the cortisol-cortisone shuttle in subcutaneous abdominal adipose tissue. Clin Endocrinol (Oxf) 1999, 50: 63-68.
39. Rask E, Olsson T, Soderberg S, et al.: Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001, 86: 1418-1421.
40. Masuzaki H, Paterson J, Shinyama H, et al.: A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294: 2166-2170.
41. Hanley AJ, Williams K, Stern MP, Haffner SM: Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002, 25: 1177-1184.
42. Resnick HE, Jones K, Ruotolo G, et al.: Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 2003, 26: 861-867.
43. Howard BV, Lee ET, Cowan LD, et al.: Rising tide of cardiovascular disease in American Indians. The Strong Heart Study. Circulation 1999, 99: 2389-2395.
44. Morrish NJ, Wang SL, Stevens LK, et al.: Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001, 44(suppl 2): S14-S21.
45. Harris MI, Flegal KM, Cowie CC, et al.: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998, 21: 518-524.
46. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287: 356-359.
47. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346: 393-403.
48. Collins R, Armitage J, Parish S, et al.: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361: 2005-2016.
49. Rossouw JE, Anderson GL, Prentice RL, et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288: 321-333.